Literature DB >> 35761037

Human papillomavirus targets the YAP1-LATS2 feedback loop to drive cervical cancer development.

Cong Huang1,2, Xiangmin Lv1, Peichao Chen1,3, Jiyuan Liu1, Chunbo He1,4, Li Chen1,5, Hongbo Wang1, Madelyn L Moness1, Jixin Dong4, Bo R Rueda1, John S Davis4,6,7, Cheng Wang8.   

Abstract

Human papillomavirus (HPV) infection is very common in sexually active women, but cervical cancer only develops in a small fraction of HPV-infected women, suggesting that unknown intrinsic factors associated with the unique genetic/genomic background of the high-risk population play a critical role in cervical carcinogenesis. Although our previous studies have identified the hyperactivated YAP1 oncogene as a critical contributor to cervical cancer, the molecular mechanism by which YAP1 drives cervical cancer is unknown. In the present study, we found that although the hyperactivated YAP1 caused a malignant transformation of immortalized cervical epithelial cells, it induced cellular senescence in cultures of primary human cervical epithelial cells (HCvECs). However, the hyperactivated YAP1 induced malignant transformation of HCvECs in the presence of high-risk HPV E6/E7 proteins, suggesting that the hyperactivated YAP1 synergizes with HPV to initiate cervical cancer development. Our mechanistic studies demonstrate that YAP1, via up-regulating LATS2, formed a YAP1-LATS2 negative feedback loop in cervical epithelial cells to maintain homeostasis of cervical tissue. Intriguingly, we found that high-risk HPV targets LATS2 to disrupt the feedback loop leading to the malignant transformation of cervical epithelial cells. Finally, we report that mitomycin C, an FDA-approved drug that could upregulate LATS2 and drive cellular senescence in vitro and in vivo, induced a regression of cervical cancer in a pre-clinial animal model. Thus, high-risk HPV targeting the YAP1-LATS2 feedback loop represents a new mechanism of cervical cancer development.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35761037     DOI: 10.1038/s41388-022-02390-y

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   8.756


  63 in total

1.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.

Authors:  J M Walboomers; M V Jacobs; M M Manos; F X Bosch; J A Kummer; K V Shah; P J Snijders; J Peto; C J Meijer; N Muñoz
Journal:  J Pathol       Date:  1999-09       Impact factor: 7.996

Review 2.  The causal relation between human papillomavirus and cervical cancer.

Authors:  F X Bosch; A Lorincz; N Muñoz; C J L M Meijer; K V Shah
Journal:  J Clin Pathol       Date:  2002-04       Impact factor: 3.411

Review 3.  Epidemiology of genital human papillomavirus infection.

Authors:  L Koutsky
Journal:  Am J Med       Date:  1997-05-05       Impact factor: 4.965

4.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

Authors:  Hyuna Sung; Jacques Ferlay; Rebecca L Siegel; Mathieu Laversanne; Isabelle Soerjomataram; Ahmedin Jemal; Freddie Bray
Journal:  CA Cancer J Clin       Date:  2021-02-04       Impact factor: 508.702

5.  Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study.

Authors:  Monica Molano; Adriaan Van den Brule; Martyn Plummer; Elisabete Weiderpass; Hector Posso; Annie Arslan; Chris J L M Meijer; Nubia Muñoz; Silvia Franceschi
Journal:  Am J Epidemiol       Date:  2003-09-01       Impact factor: 4.897

6.  Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral.

Authors:  Shalini L Kulasingam; James P Hughes; Nancy B Kiviat; Constance Mao; Noel S Weiss; Jane M Kuypers; Laura A Koutsky
Journal:  JAMA       Date:  2002-10-09       Impact factor: 56.272

Review 7.  Human Papillomavirus-Negative Cervical Cancer: A Comprehensive Review.

Authors:  Biyuan Xing; Jianfeng Guo; Yuhan Sheng; Gang Wu; Yingchao Zhao
Journal:  Front Oncol       Date:  2021-02-17       Impact factor: 6.244

8.  Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis.

Authors:  Marc Arbyn; Elisabete Weiderpass; Laia Bruni; Silvia de Sanjosé; Mona Saraiya; Jacques Ferlay; Freddie Bray
Journal:  Lancet Glob Health       Date:  2019-12-04       Impact factor: 26.763

9.  Second hit in cervical carcinogenesis process: involvement of wnt/beta catenin pathway.

Authors:  Carlos Perez-Plasencia; Alfonso Duenas-Gonzalez; Brenda Alatorre-Tavera
Journal:  Int Arch Med       Date:  2008-07-07

10.  Estimates of the global burden of cervical cancer associated with HIV.

Authors:  Dominik Stelzle; Luana F Tanaka; Kuan Ken Lee; Ahmadaye Ibrahim Khalil; Iacopo Baussano; Anoop S V Shah; David A McAllister; Sami L Gottlieb; Stefanie J Klug; Andrea S Winkler; Freddie Bray; Rachel Baggaley; Gary M Clifford; Nathalie Broutet; Shona Dalal
Journal:  Lancet Glob Health       Date:  2020-11-16       Impact factor: 26.763

View more
  1 in total

1.  Integrated analysis of cervical squamous cell carcinoma cohorts from three continents reveals conserved subtypes of prognostic significance.

Authors:  Ankur Chakravarthy; Ian Reddin; Stephen Henderson; Cindy Dong; Nerissa Kirkwood; Maxmilan Jeyakumar; Daniela Rothschild Rodriguez; Natalia Gonzalez Martinez; Jacqueline McDermott; Xiaoping Su; Nagayasau Egawa; Christina S Fjeldbo; Vilde Eide Skingen; Heidi Lyng; Mari Kyllesø Halle; Camilla Krakstad; Afschin Soleiman; Susanne Sprung; Matt Lechner; Peter J I Ellis; Mark Wass; Martin Michaelis; Heidi Fiegl; Helga Salvesen; Gareth J Thomas; John Doorbar; Kerry Chester; Andrew Feber; Tim R Fenton
Journal:  Nat Commun       Date:  2022-10-07       Impact factor: 17.694

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.